Eylea 40 mg Solution for Injection
PDF Leaflet Revision Date: 06 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various retinal diseases including wet AMD and diabetic macular edema.
Dosage (summary)
2 mg aflibercept (50 microliters) via intravitreal injection; initial monthly for 3 doses, then every 2 months.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Contraindications
- Hypersensitivity to aflibercept
- Ocular infection
- Active severe intraocular inflammation
Common side effects
- Conjunctival haemorrhage
- Eye pain
- Cataract
- Increased intraocular pressure
- Vitreous detachment
Counselling Points
- Report symptoms of endophthalmitis immediately
- Avoid driving until vision is stable after injection
Serious warnings
- Risk of endophthalmitis
- Increased intraocular pressure
- Potential arterial thromboembolic events
Important Disclaimer
The Eylea 40 mg Solution for Injection professional information leaflet below is the property of Bayer and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
